The biopharma division of IGL reported net revenue of Rs 246 crore, EBITDA of Rs 29 crore and a gross margin of 40.1% in FY26 ...

Its Rs 280 crore capital expenditure programme remains on track for completion by FY27, with Rs 160 crore already deployed ...

The company's consolidated total revenue from operations for the July–September quarter fell 29.8% to Rs. 4,247.32 crore ...

Operating performance also strengthened significantly, with consolidated EBITDA climbing 55% year-on-year to Rs 36.52 crore ...

The recommendation was made after the World Health Organization's Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) reviewed the available evidence ...